[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
[afro-nets] GFATM Terminates Nigeria HIV Grants
- From: Dieter Neuvians MD <firstname.lastname@example.org>
- Date: Mon, 01 May 2006 10:44:26 +0200
GFATM Terminates Nigeria HIV Grants for Inadequate Performance
Source: Global Fund Observer (GFO), http://www.aidspan.org/gfo/
an independent newsletter about the Global Fund provided by
In a dramatic development, the Global Fund has terminated two
HIV grants to Nigeria on the grounds that their performance has
been inadequate. This action was recommended a few months ago by
the Fund's Secretariat, but at first, when discussing the matter
by email, some board members dissented. However, by the time the
issue reached the Board meeting last week, no board members
spoke up in defence of Nigeria's handling of the grants, and the
decision to terminate the grants passed easily.
Because all grants are supposed to be "performance-based", the
Fund theoretically has the right to terminate grants at any
stage; but the most likely point for such action is when, to-
wards the end of Phase 1 (Years 1-2), the Fund assesses grants
for "Phase 2 Renewal" (covering Years 3-5). Prior to the deci-
sion about the two Nigerian grants, the Fund had issued what it
calls a "No Go" decision for only three out of 130 grants. These
were a Senegal malaria grant, a South Africa HIV/TB prevention
grant, and just last month, a Pakistan malaria grant.
The two terminated Nigerian grants were a Round 1 grant provid-
ing ARV treatment, and a Round 1 grant providing PMTCT (Preven-
tion of Mother to Child Transmission) services. The amount of
funding that Nigeria will not receive as a result of these
grants being denied Phase 2 funding is $81 million.
According to documentation provided by the Secretariat to Board
* Nigeria's ARV grant was supposed to have 14,000 people on
treatment by the end of the fourth quarter, but the actual num-
ber was zero. And it was supposed to have 24,000 on treatment by
the end of the seventh quarter, but the actual number was 6,865.
* Multiple other targets have not been met.
* Funds have been spent at a much lower rate than they should
* Questionable data has been provided to the Fund by the Princi-
pal Recipient, NACA (National Action Committee on AIDS) in
particular, at one point, numbers of people that the PR reported
as being on treatment turned out instead to be numbers of people
who could have been treated if all the drugs sent to health fa-
cilities had been used.
* Funds have been spent on inappropriate activities for in-
stance, $50,000 was spent to send fourteen people on information
missions to Botswana at a time when the grant was not perform-
* The CCM rated these grants as "B1: Adequate" when this clearly
was not the case. The CCM failed to acknowledge or report many
of the problems.
* Promised CCM reforms have not taken place.
The people who are currently receiving ARV treatment under these
grants will, despite the termination, continue to have their
treatment financed by the Fund for up to two years while alter-
native options are pursued. Furthermore, Nigeria was approved
for a major ARV grant in Round 5 that will be administered by a
different PR once the grant agreement is signed.